Tariffs, Trade, and Transformation: Safeguarding Global MedTech Supply Chains

White Paper

Tariffs, Trade, and Transformation: Safeguarding Global MedTech Supply Chains

Download the essential whitepaper for MedTech decision-makers

Sep 04, 2025

Library
Tariffs, Trade, and Transformation: Safeguarding Global MedTech Supply Chains

Are you navigating the stormy waters of international tariffs and supply chain disruption in the MedTech sector? Stay ahead with “Tariffs, Trade, and Transformation: Safeguarding Global MedTech Supply Chains” – a whitepaper from IQVIA MedTech.

Discover how ongoing changes to U.S. tariffs and retaliatory measures are reshaping the global MedTech industry, with billions at stake for leading medical device manufacturers. This comprehensive resource dives deep into the latest developments, offering clarity in these uncertain times.

Key insights from industry experts: Learn from IQVIA MedTech’s team of specialists as they analyse the projected tariff impact for 2025 and break down the implications for medical device companies of all sizes.
In-depth country risk assessment: Get an exclusive look at which markets and manufacturers will be hit hardest, and the strategies that high-threat and medium-threat countries are deploying to adapt.
Actionable strategies for resilience: Access proven approaches to mitigate tariff impacts, from supply chain diversification to pricing, regulatory intelligence, and advocacy.
Data-driven support for your business: Find out how to leverage IQVIA MedTech’s advanced tools and consulting to turn disruption into opportunity through real-world insights and scenario planning.

MedTech executives, procurement leaders, and supply chain professionals worldwide are turning to IQVIA MedTech for up-to-date intelligence and practical solutions.

Download your copy now and prepare for the challenges ahead.

Anastasia Chernyatina

Senior Consultant, IQVIA MedTech

Komal Vats

Consultant, Global Consulting Services, IQVIA MedTech

Dheeman Vaidya

Director, Business Development, IQVIA MedTech

Hear from industry trade associations

AdvaMed, MedTech Europe, and Medtech Canada discuss supply chain complexities, the need for zero-for-zero tariffs, and the importance of advocacy efforts across the MedTech industry.

Supply Chain Complexities

Oliver Bisazza, CEO at MedTech Europe, outlines why tariffs on the MedTech industry are so damaging.

Zero-for-Zero Tariffs

Ashley Miller, Executive Vice President at AdvaMed, explains the importance of having zero-for-zero tariffs in MedTech.

The Power of Advocacy

Nicole DeKort, President & CEO at Medtech Canada, urges MedTech to have a unified voice.

webinar

MedTech in Flux – Navigating Global Disruption

Hosted by IQVIA MedTech and featuring expert insights from regional trade associations AdvaMed, MedTech Canada and MedTech Europe.

Watch Now

Thrive in MedTech

Unlock MedTech success with IQVIA MedTech consulting services.

Learn More

Thrive in MedTech

Understand and anticipate global surgical trends with IQVIA’s MedTech Market Monitor.

Learn More

Thrive in MedTech

Don’t wait for a recall crisis - be prepared. Explore our Recall and Field Action Program.

Learn more

Anticipated Impacts of Recent Tariffs on the U.S. MedTech Industry Whitepaper

Read the anticipated tariff impact on the MedTech industry based on surveys of hospital and supply chain administrators.

Download

Mitigating Risk and Disruption in the MedTech Sector Whitepaper

An IQVIA MedTech Canada perspective on navigating the trade uncertainties.

Download

FAQs

U.S. tariffs have an immediate and significant impact on MedTech because of the industry’s reliance on complex global supply chains, specialized components, and lower profit margins compared to pharmaceuticals. Tariffs can raise production costs, delay product availability, and limit access to critical technologies—directly affecting patient care and innovation.

IQVIA MedTech analysis suggests tariffs could cost the MedTech sector approximately $4 billion in 2025, with worst-case modelling by AdvaMed indicating the impact could be four times higher. Large medical device manufacturers like Johnson & Johnson, Boston Scientific, and Abbott have already forecast hundreds of millions in additional costs. IQVIA MedTech Consulting Services can provide further analysis for you.

The most severely affected countries in terms of MedTech businesses could be Ireland and Costa Rica, due to the large proportion of medical devices exported to the U.S. and China, and Switzerland due to the high tariffs implemented. Reach out to IQVIA MedTech Consultants to find out more.

High-risk medical device categories include imaging systems, orthopedic implants, hearing aids, dental devices, and diagnostics—especially Class 3 and 4 devices that require stringent regulatory approval and have limited supplier options. Utilise IQVIA MedTech Consulting Services to dive deeper.

To download files, please accept Functional Cookies. These cookies provide enhanced functionality for a better user experience.